Wan Jeon1, Bum-Sup Jang1, Seung Hyuck Jeon1, Jee Hyun Kim2, Yu Jung Kim2, Se Hyun Kim2, Chae-Yong Kim3, Jung Ho Han3, In Ah Kim1,2. 1. Department of Radiation Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea. 2. Department of Internal medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea. 3. Department of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
Abstract
PURPOSE: To evaluate the survival outcomes based on molecular subtypes of breast cancer in patients with brain metastasis. MATERIALS AND METHODS: We retrospectively reviewed 106 breast cancer patients treated for brain metastases, from January 2005 to May 2016. Patients were divided into four groups based on the tumor molecular subtype: luminal A (Estrogen Receptor [ER]/Progesterone Receptor [PR] positive, human epithelial growth factor receptor-2 [HER2] negative), luminal B (ER/PR positive, HER2 Positive), HER2 (HER2 positive and ER/PR negative), and Triple negative (TNBC). RESULTS: The median follow-up time for surviving patients was 22 months (range: 11.2-51.1 months). The median survival of all patients was 14 months, with a 1-year overall survival (OS) rate of 57.5% and a 2-year OS rate of 32.1%. Thirty patients (28.3%) had a solitary brain metastasis while 62 (58.5%) patients had multiple metastases. A significant difference was observed in the survival rates of the two groups. Based on the Karnofsky performance score, the performance status of the patients at the time of brain metastasis was also found to affect survival. Patients with different molecular subtypes had different survival rates; the luminal A group showed the highest median survival (luminal A: 23.1, luminal B: 15.0, HER2: 12.5 and TNBC: 6.4 months, respectively), which was statistically significant. CONCLUSION: In breast cancer patients with brain metastasis, survival rates were different based on the molecular subtype of the tumor, despite various local and systemic treatments. Appropriate and tailored treatment approaches should, therefore, be considered for the different molecular subtypes.
PURPOSE: To evaluate the survival outcomes based on molecular subtypes of breast cancer in patients with brain metastasis. MATERIALS AND METHODS: We retrospectively reviewed 106 breast cancerpatients treated for brain metastases, from January 2005 to May 2016. Patients were divided into four groups based on the tumor molecular subtype: luminal A (Estrogen Receptor [ER]/Progesterone Receptor [PR] positive, human epithelial growth factor receptor-2 [HER2] negative), luminal B (ER/PR positive, HER2 Positive), HER2 (HER2 positive and ER/PR negative), and Triple negative (TNBC). RESULTS: The median follow-up time for surviving patients was 22 months (range: 11.2-51.1 months). The median survival of all patients was 14 months, with a 1-year overall survival (OS) rate of 57.5% and a 2-year OS rate of 32.1%. Thirty patients (28.3%) had a solitary brain metastasis while 62 (58.5%) patients had multiple metastases. A significant difference was observed in the survival rates of the two groups. Based on the Karnofsky performance score, the performance status of the patients at the time of brain metastasis was also found to affect survival. Patients with different molecular subtypes had different survival rates; the luminal A group showed the highest median survival (luminal A: 23.1, luminal B: 15.0, HER2: 12.5 and TNBC: 6.4 months, respectively), which was statistically significant. CONCLUSION: In breast cancerpatients with brain metastasis, survival rates were different based on the molecular subtype of the tumor, despite various local and systemic treatments. Appropriate and tailored treatment approaches should, therefore, be considered for the different molecular subtypes.
Authors: Daisuke Yamashita; Mutsuko Minata; Ahmed N Ibrahim; Shinobu Yamaguchi; Vito Coviello; Joshua D Bernstock; Shuko Harada; Richard A Cerione; Bakhos A Tannous; Concettina La Motta; Ichiro Nakano Journal: Mol Cancer Ther Date: 2020-03-03 Impact factor: 6.261
Authors: José Manuel Sánchez-Villalobos; Alfredo Serna-Berna; Juan Salinas-Ramos; Pedro Pablo Escolar-Pérez; Emma Martínez-Alonso; Daniel G Achel; Miguel Alcaraz Journal: Colomb Med (Cali) Date: 2021-06-09
Authors: Henry Ruiz-Garcia; Lina Marenco-Hillembrand; Jennifer L Peterson; Katherine Tzou; Timothy D Malouff; Kaisorn L Chaichana; Daniel M Trifiletti; Laura Vallow Journal: Transl Cancer Res Date: 2020-01 Impact factor: 1.241